netFormulary
 Report : Medicines with links to NICE 05/12/2020 22:32:19

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abiraterone 08.03.04.02 Restricted Use NICE TA259: Abiraterone for castration resistant prostate cancer
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adefovir Dipivoxil 05.03.03 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil 05.03.03 Restricted Use NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Aflibercept 08.01 Formulary NICE TA307 - Colorectal cancer (metastatic) - aflibercept: guidance
Aflibercept 11.08.02 Restricted Use NICE TA294: Macular degeneration (wet age-related) - aflibercept
Alirocumab 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Restricted Use NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
Apremilast 08.02 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 08.02 Restricted Use NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Restricted Use NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213)
Aripiprazole 04.02.01 Restricted Use NICE TA292: Bipolar disorder (children) - aripiprazole (NICE TA292)
Aspirin (antiplatelet) 02.09 Formulary NICE CG107 - Hypertension in pregnancy
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benzyl penicillin 24.01 Restricted Use NICE
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin 02.08.01 Formulary NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02.03 Restricted Use NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03 Formulary NICE Guidance 2012
Bortezomib 08.01.05 Restricted Use NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Restricted Use NICE TA228:Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Botulinum Toxin Type A 04.07.04.02 Non Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.01.05 Formulary NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Cabazitaxel 08.01.05 Restricted Use NICE TA255: Cabazitaxel for prostate cancer
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Restricted Use TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Restricted Use NICE TA186: Rheumatoid arthritis - certolizumab pegol
Cetuximab 08.01.05 Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Crizotinib 08.01.05 Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dapagliflozin 06.01.02.03 Non Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dasatinib 08.01.05 Restricted Use NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Diltiazem Cream 2% 01.07.04 Restricted Use NICE evidence summary
Docetaxel 08.01.05 Formulary NICE CG121: Lung Cancer - The diagnosis and treatment of lung cancer
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Domperidone 04.06 Formulary NICE: Promoting tolerance of enteral feeds in children and young people: domperidone
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Restricted Use NICE TA197: Atrial fibrillation - dronedarone
Eltrombopag 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Empagliflozin 06.01.02.03 Restricted Use NICE TA336- Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Restricted Use NICE TA390- Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03 Restricted Use NICE TA153: Hepatitis B (chronic) - etecavir
Entecavir 05.03.03 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Eplerenone 02.02.03 Restricted Use NICE CG108: Chronic heart failure
Eribulin 08.01.05 Restricted Use NICE TA250: Breast cancer (advanced) - eribulin (TA250)
Erlotinib 08.01.05 Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Restricted Use NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Everolimus 08.01.05 Restricted Use NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Restricted Use NICE TA294: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Everolimus 08.01.05 Restricted Use NICE TA219: Everolimus for second-line treatment of renal cell cancer
Evolocumab 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 06.01.02.03 Non Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Non Formulary NICE TA132: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA271: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gentamicin 24.01 Restricted Use NICE Guidance
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Restricted Use NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA225: Rheumatoid arthritis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA233: Ankylosing spondylitis - golimumab
Ibrutinib 08.01.05 Restricted Use NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Imatinib 08.01.05 Restricted Use NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Restricted Use NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Restricted Use NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Restricted Use NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): guidance
Imatinib 08.01.05 Restricted Use NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Ipilimumab 08.01.05 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Restricted Use NICE Guidance on Stable Angina
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Liraglutide 06.01.02.03 Formulary NICE CG28: Type 2 diabetes in adults: management
Magnesium Glycerophosphate 09.05.01.03 Formulary NICE: Evidence Summary: Magnesium glycerophosphate
Mannitol inhalation 03.07 Non Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Methylprednisolone 06.03.02 Formulary NICE: Multiple Sclerosis; management in primary and secondary care.
MIDODRINE Tablets 2.5 mg, 5mg 02.07.02 Formulary NICE: Postural hypotension in adults: midodrine (ESUOM5)
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Modafinil 04.04 Restricted Use NICE: Evidence Summary (Apr 2013)
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nivolumab 08.01 Restricted Use NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01 Restricted Use NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma (November 2016)
Obeticholic acid 01.09.01 Restricted Use NICE Ta 443: for primary biliary cholangitis
Ocriplasmin 11.08.02 Restricted Use NICE TA297: Ocriplasmin for treating vitreomacular traction
Omalizumab 03.04.02 Formulary NICE TA201: Asthma (in children) - omalizumab
Omalizumab 03.04.02 Formulary NICE TA133: Asthma (uncontrolled) - omalizumab
Omega-3-Acid Ethyl Esters 02.12 Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Panitumumab 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.02.03 Restricted Use NICE TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.02.03 Restricted Use NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.02.03 Restricted Use NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.02.03 Restricted Use NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Perampanel 04.08.01 Restricted Use NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Perampanel 04.08.01 Restricted Use NICE evidence summary
Perampanel 04.08.01 Restricted Use NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pimecrolimus 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 17 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone (TA282)
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Restricted Use NICE TA182: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE quick reference guide on osteoporosis
Raltitrexed 08.01.03 Formulary NICE CG131 - Colorectal Cancer: The diagnosis and management of colorectal cancer
Ranibizumab 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranolazine 02.06.03 Formulary NICE Guidance on Stable Angina
Retigabine 04.08.01 Restricted Use NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 08.02.03 Restricted Use NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab
Rituximab 08.02.03 Restricted Use NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Roflumilast 03.03.03 Non Formulary NICE Final Appraisal Determination Dec 2011
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Secukinumab 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Somatropin 06.05.01 Non Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Non Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib 08.01.05 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Tacrolimus 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Non Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Non Formulary NICE Guidance 2012
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir Disproxil 05.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA173
Ticagrelor 02.09 Restricted Use NICE TA236
Tinzaparin 02.08.01 Formulary NICE guideline [NG89] March 2018: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Restricted Use NICE TA198: Rheumatoid arthritis - tocilizumab
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA91: Topotecan for ovarian cancer
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vemurafenib 08.01.05 Non Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
VibeX Rapid 11.08.02 Restricted Use NICE IPG466- Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Zolpidem 04.01.01 Restricted Use NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Restricted Use NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Bradford Teaching Hospitals